A missense TCF1 mutation in a patient with mody-3 and liver adenomatosis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed, 21 citations in OpenAlex.

1. An "unclassified diabetes" after a long duration of disease in a young subject: a case report.The Pan African medical journal · 2025
   Article
2. Molecular diagnosis of maturity onset diabetes of the young in India.Indian journal of endocrinology and metabolism · 2013
   Article
3. Early onset of liver steatosis in a Japanese girl with maturity-onset diabetes of the young type 3 (MODY3).Journal of clinical research in pediatric endocrinology · 2012
   Article
4. Screening for hotspot mutations in PI3K, JAK2, FLT3 and NPM1 in patients with myelodysplastic syndromes.Clinics (Sao Paulo, Brazil) · 2011
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

6 authors at 2 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as